Detalhe da pesquisa
1.
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Lancet Oncol
; 23(12): 1571-1582, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36370716
2.
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1458-1467, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34543613
3.
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.
Int J Cancer
; 147(1): 160-169, 2020 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31724170
4.
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.
EClinicalMedicine
; 59: 101931, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-37256095